Higher Premiums, Out-Of-Pocket Costs Drive Higher Health Care Financial Burden

The nearly 180 million Americans with private health insurance coverage have experienced increased premiums and decreased benefits. However, little is known about how changes in privately insured families’ contributions to insurance premiums and out-of-pocket spending have affected the financial burden of health care over the past two decades.

“This issue is particularly salient for those with low incomes, who are more susceptible to debt, bankruptcy and worse health outcomes due to poverty,” according to a study reported in JAMA Internal Medicine. “Understanding changes in the financial burden of health care has important implications for patients and policymakers, who have made addressing care affordability a priority.”

Researchers used Medicare Expenditure Panel Survey data from 2007 to 2019 for respondents and family members younger than 65 with private insurance. Families’ total health care spending was calculated as contributions to premiums plus out-of-pocket medical and prescription drug spending. Families’ annual financial medical burden was assessed by dividing total health care spending by post-subsistence income, which is income minus estimated food costs.

The inflation-adjusted mean total health care spending by privately insured families increased from $3,920 in 2007 to $4,907 in 2019, largely because of higher premium contributions. This increase affected all income groups:

  • Among low-income families, mean total health care spending was $3,163 in 2007 and $3247 in 2019.
  • Among higher-income families, mean total health care spending increased from $4,071 in 2007 to $5,239 in 2019.
  • The mean financial medical burden was more than 26% of post-subsistence income for low-income families, compared with approximately 6% for higher-income families.
  • Although premiums increased across all income groups, out-of-pocket spending remained stable over time.

The findings highlight the need to strengthen financial safeguards for low-income families, including those that do not meet enhanced state definitions of Medicaid eligibility and are considered well-resourced enough to rely on private insurance, researchers said. Furthermore, these results suggest that without stronger emphasis on regulating premiums, controlling out-of-pocket costs is necessary but not sufficient to alleviate the burden of health care.

“Factors underlying increasing premiums include aging enrollees with increasing utilization, increasing administrative and specialty drug costs, market consolidation and insurers’ interests in profitability,” the report concluded. “Policymakers might consider strengthening income-based subsidies, improving drug price negotiation and bolstering antitrust scrutiny to help contain the costs of premiums.”

 

Source Link

Recommended Articles

New NFIB Survey: Small Businesses Report Reduced Optimism

The NFIB Small Business Optimism Index fell 0.6 points in May to 95.3, remaining below its 52-year average of 98.0. The Uncertainty Index rose 3 points from April to 91, remaining well above its historical average of 68. As reported in NFIB’s monthly Jobs Report, the NFIB Small Business Employment Index remained essentially flat, registering 100.3 in May. ...

Read More

Trump Announces TrumpRx Expansion, Adding 160 More Drugs

President Trump on Friday announced that over 100 prescription medications would be added to his administration’s direct-to-consumer drug platform, TrumpRx, the second expansion of the initiative in as many months. “I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs,” ...

Read More

Skyrocketing GLP-1 Demand Creates Major Financial Strain For Employers

GLP-1 drugs are a double-edged sword for the nation’s employers. Although they are having a demonstrable effect on workplace health, the high cost is putting a strain on their budgets. GLP-1s, known by brand names such as Ozempic, Wegovy, Mounjaro or Zepbound, originally were developed to help regulate blood sugar in people with Type 2 ...

Read More

Judge Throws Out Policy Imposing $100,000 Fees for Skilled Worker Visas

A Trump administration initiative to impose $100,000 fees on employers seeking visas for skilled foreign workers amounts to an unlawful tax on those companies and must be voided “in its entirety,” a federal judge ruled on Monday. The decision by Judge Leo T. Sorokin of the Federal District Court for the District of Massachusetts nullified ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square